How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

Core Viewpoint - AstraZeneca (AZN) shows potential for further upside, with a mean price target of $86.07 indicating a 27.9% increase from its current price of $67.30 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $10.38, indicating variability among analysts [2] - The lowest estimate is $67, suggesting a 0.5% decline, while the highest estimate is $103, indicating a potential increase of 53.1% [2] - A low standard deviation signifies strong agreement among analysts regarding price movement direction [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about AZN's earnings prospects, as indicated by upward revisions in EPS estimates [11] - Over the past 30 days, two estimates have increased, leading to a 0.2% rise in the Zacks Consensus Estimate [12] - AZN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely predict actual stock price movements [7] - Analysts may set overly optimistic targets due to business incentives, which can inflate price expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]